A Cleveland Clinic-led trial found that testosterone-replacement therapy did not result in a higher incidence of major adverse cardiac events in middle-aged and older men with hypogonadism (also known as low testosterone) who also had preexisting or a high risk of cardiovascular disease. However, researchers still urge caution when considering testosterone therapy. Dr. Steve Nissen discusses the results of the TRAVERSE trial.